우리나라 만성 C형간염 환자에서 페그인터페론과 리바비린의 병합치료에 대한 효과
Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection
2
조회
0
다운로드
10
인용
0
참고문헌
초록
Background/Aims: We assessed the efficacy and safety of pegylated interferon (peginterferon) plus ribavirin and identified the predictors of a sustained virologic response (SVR) in Korean patients with chronic hepatitis C virus infection. Methods: A total of 192 patients with chronic hepatitis C, treated with both peginterferon (n=141) or conventional interferon (n=51) and ribavirin, were analyzed retrospectively. Peginterferon alfa-2a (180 µg/week) or -2b (1.5 µg/kg/week) or interferon alfa-2a (3 MIU thrice weekly) was administered in combination with ribavirin at 1,000-1,200 mg/day for 48 weeks for genotype 1 and at 800 mg/day for 24 weeks for genotypes 2 and 3. Results: The overall SVR rate was 80.9% (114/141) in the peginterferon group and 52.9% (27/51) in the interferon group (P=0.0001). The SVR rate in genotype 1 was 69.5% (41/59) in the peginterferon group and 31.6% (6/19) in the interferon group (P=0.0033), whereas in genotype 2 or 3 it was 89.0% (73/82) in the peginterferon group and 65.6% (21/32) in the interferon group (P=0.0032). The predictors of SVR in the peginterferon group were genotype, absence of cirrhosis, and early virologic response (P<0.05). Conclusions: In Korean patients with chronic hepatitis C, a regimen of peginterferon and ribavirin was more effective than a regimen of conventional interferon and ribavirin. This result is comparable to those from studies on Western patients as an initial treatment for chronic hepatitis C.
Abstract
Background/Aims: We assessed the efficacy and safety of pegylated interferon (peginterferon) plus ribavirin and identified the predictors of a sustained virologic response (SVR) in Korean patients with chronic hepatitis C virus infection. Methods: A total of 192 patients with chronic hepatitis C, treated with both peginterferon (n=141) or conventional interferon (n=51) and ribavirin, were analyzed retrospectively. Peginterferon alfa-2a (180 µg/week) or -2b (1.5 µg/kg/week) or interferon alfa-2a (3 MIU thrice weekly) was administered in combination with ribavirin at 1,000-1,200 mg/day for 48 weeks for genotype 1 and at 800 mg/day for 24 weeks for genotypes 2 and 3. Results: The overall SVR rate was 80.9% (114/141) in the peginterferon group and 52.9% (27/51) in the interferon group (P=0.0001). The SVR rate in genotype 1 was 69.5% (41/59) in the peginterferon group and 31.6% (6/19) in the interferon group (P=0.0033), whereas in genotype 2 or 3 it was 89.0% (73/82) in the peginterferon group and 65.6% (21/32) in the interferon group (P=0.0032). The predictors of SVR in the peginterferon group were genotype, absence of cirrhosis, and early virologic response (P<0.05). Conclusions: In Korean patients with chronic hepatitis C, a regimen of peginterferon and ribavirin was more effective than a regimen of conventional interferon and ribavirin. This result is comparable to those from studies on Western patients as an initial treatment for chronic hepatitis C.
참고문헌 (33)
- McHutchison JG, "Understanding hepatitis C", Am J Manag Care, 10(Suppl 2), pp.21~29 (2004)
- Alter MJ, "The prevalence of hepatitis C virus infection in the United States, 1988 through 1994", N Engl J Med, 341, pp.556~562 (1994)
- Conry-Cantilena C, "Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection", N Engl J Med, 334, pp.1691~1696 (1996)
- Shin HR, "Epidemiology of hepatitis C virus in Korea", Intervirology, 49, pp.18~22 (2006)
- Hu KQ, "The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in United States", Hepatology, 29, pp.1311~1316 (1999)
- Serfaty L, "Determinants of outcome of compensated hepatitis C virus-related cirrhosis", Hepatology, 27, pp.1435~1440 (1998)
- Fattovich G, "Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients", Gastroenterology, 112, pp.463~472 (1997)
- Davis GL, "Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial", N Engl J Med, 321, pp.1501~1506 (1989)
- Poynard T, "Meta-analysis of interferon randomized trials in the treatment of viral hepatits C: effects of dose and duration", Hepatology, 24, pp.778~789 (1996)
- McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C", N Engl J Med, 339, pp.1485~1492 (1998)
- Glue P, "Pegylated interferon-alfa2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data", Clin Pharmacol Ther, 68, pp.556~567 (2000)
- Zeuzem S, "Peginterferon alfa-2a in patients with chronic hepatitis C", N Engl J Med, 343, pp.1666~1672 (2000)
- Lindsay KL, "A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa- 2b as initial treatment for chronic hepatitis C", Hepatology, 34, pp.395~403 (2001)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Lee HJ, "Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha- 2b plus ribavirin according to treatment duration in patients with chronic hepatitis C", Korean J Hepatol, 14, pp.46~57 (2008)
- Kim KT, "Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C", Korean J Hepatol, 14, pp.36~45 (2008)
- Lee H, "Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea", Korean J Hepatol, 12, pp.31~40 (2006)
- Treatment guidelines for chronic hepatitis C, "The Korean association for the study of the liver", Korean J Hepatol, 10(Suppl), pp.101~125 (2004)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Kuboki M, "Peginterferon alpha2a (40KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients", J Gastroenterol Hepatol, 22, pp.645~652 (2007)
- Yu JW, "Predictive value of rapid virologic response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha2a and ribavirin", J Gastroenterol Hepatol, 22, pp.832~836 (2007)
- Lee SD, "Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan", J Viral Hepat, 12, pp.283~291 (2005)
- Dev AT, "Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome", Hepatology, 36, pp.1259~1265 (2002)
- Hepburn MJ, "Differences in treatment outcome for hepatitis C among ethnic groups", Am J Med, 117, pp.163~168 (2004)
- McHutchison JG, "Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C", Gastroenterology, 123, pp.1061~1069 (2002)
- Davis GL, "Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C", Hepatology, 38, pp.645~652 (2003)
- National Institutes of Health, "National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C", Hepatology, 36(Suppl 1), pp.3~20 (2002)
- Lee SS, "Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)", J Hepatol, 37, pp.500~506 (2002)
- Ferenci P, "Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)", ribavirin, 2005, pp.43, 425~433
- Zeuzem S, "Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa", Hepatology, 27, pp.1149~1156 (1998)
- Zeuzem S, "Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia", J Hepatol, 44, pp.97~103 (2006)
- Fried MW, "Side effects of therapy of hepatitis C and their management", Hepatology, 36(Suppl 1), pp.237~244 (2002)